Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma CC-92328

What's the purpose of this trial?

This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM).

This trial is currently open and accepting patients.

What will happen during the trial?


You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Participants must satisfy the following criteria to be enrolled in the study:
    • Must understand and voluntarily sign an informed consent form (ICF) prior to any study-related assessments/procedures being conducted.
    • willing and able to adhere to the study visit schedule and other protocol requirements.
    • Participant is ≥ 18 years of age the time of signing the ICF.
    • Participant has a history of multiple myeloma (MM) with relapsed and/or refractory disease who have failed or who are ineligible or intolerant to available therapies that may provide clinical benefit.
    • Have documented disease progression on or within 12 months from the last dose of their last myeloma therapy.
    • Participant must have measurable disease.
    • Participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
    • Females of childbearing potential (FCBP) must commit to true abstinence from heterosexual contact or agree to use at least one method of highly effective contraception without interruption from screening to at least 9 weeks after the last dose of CC-92328
    • Males must practice true abstinence or agree to use a condom
    • FCBP and males must avoid conceiving from signing the ICF, while participating in the study, during dose interruptions, and for at least 9 weeks after the last dose of CC-92328.

Exclusion Criteria:

  • The presence of any of the following will exclude a participant from enrollment:
    • Participant has symptomatic central nervous system involvement of MM.
    • Participant had a prior autologous stem cell transplant ≤ 90 days prior to starting CC-92328.
    • Participant had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 12 months prior to starting CC-92328.
    • Participant had prior systemic cancer-directed treatments or investigational modalities ≤ 5 half-lives or 4 weeks prior to starting CC-92328, whichever is shorter.
    • Participant is a pregnant or lactating female.
    • Participant received live virus vaccines within at least 4 weeks prior to starting study drug.
    • Participant has known active human immunodeficiency virus (HIV) infection.
    • Participant has active hepatitis B or C (HBV/HCV) infection.
    • Participant weight is ≤ 40 kg at screening.

Additional Trial Information

Phase 1

Enrollment: 70 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


University of Alabama at Birmingham O'Neal Comprehensive Cancer Center at UAB

Birmingham, AL

Open and Accepting


HonorHealth Research and Innovation Institute

Scottsdale, AZ

Open and Accepting


New York

Memorial Sloan Kettering Cancer Center

New York, NY

Open and Accepting

Mount Sinai Hospital Tisch Cancer Institute

New York, NY

Open and Accepting


Medical College of Wisconsin Froedtert Hospital

Milwaukee, WI

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors